CN114007625A - 用于治疗眼病的化合物和方法 - Google Patents

用于治疗眼病的化合物和方法 Download PDF

Info

Publication number
CN114007625A
CN114007625A CN202080044806.4A CN202080044806A CN114007625A CN 114007625 A CN114007625 A CN 114007625A CN 202080044806 A CN202080044806 A CN 202080044806A CN 114007625 A CN114007625 A CN 114007625A
Authority
CN
China
Prior art keywords
alkyl
compound
optionally substituted
oxy
heteroalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080044806.4A
Other languages
English (en)
Chinese (zh)
Inventor
伊恩·霍尔姆斯
亚伊尔·阿尔斯特
希拉·巴拉什
查尔斯·博斯沃斯
奥默·拉法尔里
马克·格利森
马克·理查德·斯图尔特
乔纳森·杜恩
罗伯特·M·伯克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mg Therapeutics Ltd
Original Assignee
Mg Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mg Therapeutics Ltd filed Critical Mg Therapeutics Ltd
Publication of CN114007625A publication Critical patent/CN114007625A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CN202080044806.4A 2019-04-18 2020-04-16 用于治疗眼病的化合物和方法 Pending CN114007625A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962835975P 2019-04-18 2019-04-18
US62/835,975 2019-04-18
US202062966482P 2020-01-27 2020-01-27
US62/966,482 2020-01-27
PCT/IB2020/000312 WO2020212760A2 (en) 2019-04-18 2020-04-16 Compounds and methods for the treatment of ocular disorders

Publications (1)

Publication Number Publication Date
CN114007625A true CN114007625A (zh) 2022-02-01

Family

ID=72837068

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044806.4A Pending CN114007625A (zh) 2019-04-18 2020-04-16 用于治疗眼病的化合物和方法

Country Status (9)

Country Link
US (2) US11643429B2 (https=)
EP (1) EP3955937A4 (https=)
JP (1) JP2022529315A (https=)
KR (1) KR20210154214A (https=)
CN (1) CN114007625A (https=)
AU (1) AU2020259997B2 (https=)
CA (1) CA3136369A1 (https=)
IL (1) IL287280A (https=)
WO (1) WO2020212760A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116940570A (zh) * 2020-10-21 2023-10-24 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3955937A4 (en) 2019-04-18 2023-01-18 Azura Ophthalmics Ltd. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
JP7700045B2 (ja) 2019-04-18 2025-06-30 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法
IL302173A (en) * 2020-10-21 2023-06-01 Azura Ophthalmics Ltd Compounds and methods for the treatment of ocular disorders
EP4419502A4 (en) * 2021-10-20 2025-10-29 Azura Ophthalmics Ltd COMPOUNDS AND METHODS FOR THE TREATMENT OF SKIN AND OCULAR DISORDERS
TW202421700A (zh) 2022-07-28 2024-06-01 日商住友化學股份有限公司 偏光膜的製造方法及製造裝置
WO2024101918A1 (ko) * 2022-11-11 2024-05-16 주식회사 메디치바이오 리포-하이드록삼산 유도체 및 이의 약학적 용도
WO2024134266A1 (en) * 2022-12-20 2024-06-27 Azura Ophthalmics Ltd. Compounds and methods for the treatment of dermal and ocular disorders
WO2025012700A2 (en) * 2023-07-07 2025-01-16 Azura Ophthalmics Ltd. Compositions and methods for the treatment of autoimmune disorders

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816557A (zh) * 2003-05-13 2006-08-09 葛兰素集团有限公司 新型14和15元环化合物
CN1820017A (zh) * 2003-05-13 2006-08-16 葛兰素集团有限公司 4＂位取代的大环内酯类
CN1837225A (zh) * 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
CN1852912A (zh) * 2003-05-13 2006-10-25 葛兰素集团有限公司 新型14和15元环化合物
WO2013003731A2 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
US20130045938A1 (en) * 2010-02-15 2013-02-21 Synovo Gmbh Kinase modulators for the treatment of cancer
WO2018161039A1 (en) * 2017-03-03 2018-09-07 Synovo Gmbh Novel anti-infective and anti-inflammatory compounds
WO2018215638A1 (en) * 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
US5350839A (en) * 1990-10-15 1994-09-27 Taisho Pharmaceutical Co., Ltd. 2'-position modified compound of erythromycin or its derivative
WO1995018604A1 (en) * 1994-01-11 1995-07-13 Ciba-Geigy Ag Topical treatment of ocular photophobia
ES2293638T3 (es) 1994-03-25 2008-03-16 Isotechnika, Inc. Mejora de la eficacia de farmacos por deuteracion.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US7056893B2 (en) 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
EP1101769A3 (en) * 1999-11-18 2001-10-24 Pfizer Products Inc. Nitrogen containing erythromycin derivatives
RU2263117C2 (ru) * 2001-04-27 2005-10-27 Пфайзер Продактс Инк. Способ получения 4"-замещенных производных 9-деоксо-9а-аза-9а-гомоэритромицина а
FR2832637B1 (fr) * 2001-06-07 2004-07-30 Lefaix Marie Therese Droy Utilisation d'un antioxydant pour la fabrication d'un medicament destine au traitement des affections oculaires de surface
AU2003219770B2 (en) * 2002-02-15 2008-10-09 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
GB0609373D0 (en) * 2006-05-11 2006-06-21 Glaxo Group Ltd Macrolones
PE20090879A1 (es) * 2007-07-30 2009-07-25 Glaxosmithkline Zagreb DERIVADOS 9-DESOXO-9a-METIL-9a-AZA-9a-HOMOERITROMICINA A COMO AGENTES ANTIMALARICOS
WO2010086350A1 (en) * 2009-01-30 2010-08-05 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. 9-deoxo- 9a-methyl- 9a- aza- 9a-h0m0erythr0mycin a derivatives for the treatment of neutrophil dominated inflammatory diseases
AU2013239679A1 (en) * 2012-03-27 2014-10-30 Michael W. BURNET Anti-inflammatory macrolides
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
JP2019513775A (ja) 2016-04-19 2019-05-30 アズーラ オフサルミックス エルティーディー． 角化症の処置のための組成物
EP3600272A4 (en) 2017-03-29 2021-01-13 Azura Ophthalmics Ltd. MEANS OF INCREASING LIPID SECRETION OF THE MEIBOMAN GLAND
EP3955937A4 (en) 2019-04-18 2023-01-18 Azura Ophthalmics Ltd. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1816557A (zh) * 2003-05-13 2006-08-09 葛兰素集团有限公司 新型14和15元环化合物
CN1820017A (zh) * 2003-05-13 2006-08-16 葛兰素集团有限公司 4＂位取代的大环内酯类
CN1852912A (zh) * 2003-05-13 2006-10-25 葛兰素集团有限公司 新型14和15元环化合物
CN1837225A (zh) * 2005-08-23 2006-09-27 济南思创生物技术有限公司 阿奇霉素衍生物及其制法和药物应用
US20130045938A1 (en) * 2010-02-15 2013-02-21 Synovo Gmbh Kinase modulators for the treatment of cancer
WO2013003731A2 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
WO2018161039A1 (en) * 2017-03-03 2018-09-07 Synovo Gmbh Novel anti-infective and anti-inflammatory compounds
WO2018215638A1 (en) * 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JING QIAO 等: "E merging treatment options for meibomian gland dysfunction", 《CLINICAL OPHTHALMOLOGY》, vol. 7, pages 1797 - 1803 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116940570A (zh) * 2020-10-21 2023-10-24 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法

Also Published As

Publication number Publication date
IL287280A (en) 2021-12-01
EP3955937A4 (en) 2023-01-18
JP2022529315A (ja) 2022-06-21
WO2020212760A2 (en) 2020-10-22
KR20210154214A (ko) 2021-12-20
AU2020259997B2 (en) 2025-08-07
AU2020259997A1 (en) 2021-11-25
CA3136369A1 (en) 2020-10-22
US20230348517A1 (en) 2023-11-02
US11643429B2 (en) 2023-05-09
US20210230205A1 (en) 2021-07-29
WO2020212760A3 (en) 2021-02-25
EP3955937A2 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
CN114007625A (zh) 用于治疗眼病的化合物和方法
JP7700045B2 (ja) 眼障害を処置するための化合物および方法
AU2021363702A1 (en) Compounds and methods for the treatment of ocular disorders
WO2020212755A1 (en) Compounds and methods for the treatment of ocular disorders
KR20230110514A (ko) 안구 장애의 치료를 위한 화합물 및 방법
US20250042931A1 (en) Compounds and methods for the treatment of ocular disorders
HK40068817A (en) Compounds and methods for the treatment of ocular disorders
CN116635032A (zh) 用于治疗眼部病症的化合物和方法
HK40068671A (en) Compounds and methods for the treatment of ocular disorders
CN116940570A (zh) 用于治疗眼部病症的化合物和方法
JP2024538954A (ja) 皮膚および眼の障害を処置するための化合物および方法
HK40102653A (zh) 用於治疗眼部病症的化合物和方法
HK40100091A (zh) 用於治疗眼部病症的化合物和方法
JP2025542255A (ja) 皮膚および眼の障害を処置するための化合物および方法
HK40100700A (zh) 用於治疗眼部病症的化合物和方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40068817

Country of ref document: HK